KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) EBITDA Margin (2019 - 2025)

Aurinia Pharmaceuticals' EBITDA Margin history spans 7 years, with the latest figure at 273.55% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 27160.0% year-over-year to 273.55%; the TTM value through Dec 2025 reached 101.48%, up 9900.0%, while the annual FY2025 figure was 101.48%, 9900.0% up from the prior year.
  • EBITDA Margin reached 273.55% in Q4 2025 per AUPH's latest filing, up from 43.16% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 273.55% in Q4 2025 to a low of 5511.27% in Q1 2021.
  • Average EBITDA Margin over 5 years is 345.8%, with a median of 26.15% recorded in 2023.
  • Peak YoY movement for EBITDA Margin: skyrocketed 14493321bps in 2021, then plummeted -900bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 142.63% in 2021, then soared by 37bps to 89.96% in 2022, then surged by 34bps to 59.12% in 2023, then soared by 103bps to 1.95% in 2024, then surged by 13933bps to 273.55% in 2025.
  • Per Business Quant, the three most recent readings for AUPH's EBITDA Margin are 273.55% (Q4 2025), 43.16% (Q3 2025), and 30.62% (Q2 2025).